Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) has submitted supplemental new drug applications (NDAs) for dabrafenib/trametinib combination in metastatic melanoma to the US Food and Drug Administration (FDA).
Subscribe to our email newsletter
The applications were submitted for the use of each drug dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, in combination with the other to treat adult patients with unresectable or metastatic melanoma with a BRAF V600 E or K mutation.
Data from a randomised Phase I/II study that compared dabrafenib monotherapy to combination therapy with dabrafenib and trametinib in patients with BRAF V600E and V600K mutation positive metastatic melanoma support the applications.
The MAA of trametinib, both as monotherapy and in combination with dabrafenib, is currently being reviewed in Europe.